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Introduction {#cam4985-sec-0001}
============

Neoadjuvant chemotherapy is offered to breast cancer patients with inoperable tumors or tumors that are too large for breast conservation, in order to allow for possible resection or breast conservation, respectively [1](#cam4985-bib-0001){ref-type="ref"}. It provides comparable survival benefits to adjuvant chemotherapy for breast cancer [2](#cam4985-bib-0002){ref-type="ref"}, [3](#cam4985-bib-0003){ref-type="ref"}, [4](#cam4985-bib-0004){ref-type="ref"}, [5](#cam4985-bib-0005){ref-type="ref"}. Pathologic complete response (pCR), which is associated with excellent long‐term prognosis, was reported to be up to 45.8% when definition of pCR was taken as absence of invasive tumor in the breast but allow for in situ tumor [6](#cam4985-bib-0006){ref-type="ref"}, [7](#cam4985-bib-0007){ref-type="ref"}. pCR ranges from 12% to 19.4% across various study populations when defined as no residual invasive or in situ tumor in the breast and axillary lymph nodes [8](#cam4985-bib-0008){ref-type="ref"}, [9](#cam4985-bib-0009){ref-type="ref"}.

In most Asian countries, breast cancer rates have been on the rise over the past two decades [10](#cam4985-bib-0010){ref-type="ref"}, [11](#cam4985-bib-0011){ref-type="ref"}, [12](#cam4985-bib-0012){ref-type="ref"}, [13](#cam4985-bib-0013){ref-type="ref"} and these Asian women present to a large extent with more advanced disease [14](#cam4985-bib-0014){ref-type="ref"}. Given that Asian women present with larger tumors, neoadjuvant chemotherapy plays an even more important role. Most large multi‐center studies are done in the United States, Europe, and Australia [15](#cam4985-bib-0015){ref-type="ref"}, [16](#cam4985-bib-0016){ref-type="ref"}, with few done specifically in Asia. Varying use of fourth‐generation chemotherapy as well as trastuzumab for human epidermal growth factor receptor 2 (HER2)‐positive disease were reported in published studies [6](#cam4985-bib-0006){ref-type="ref"}, [16](#cam4985-bib-0016){ref-type="ref"}, [17](#cam4985-bib-0017){ref-type="ref"}, [18](#cam4985-bib-0018){ref-type="ref"}. Given the above difference in epidemiology of breast cancer patients in Asia as compared to non‐Asian patients, we aim to identify clinicopathologic and therapeutic predictors for response to neoadjuvant chemotherapy and evaluate the prognostic value of pCR on overall survival in a multi‐ethnic Asian setting.

Materials and Methods {#cam4985-sec-0002}
=====================

A total of 915 nonmetastatic breast cancer patients, who underwent neoadjuvant chemotherapy and subsequently had breast surgery, were identified from four public tertiary hospitals in Singapore and one tertiary hospital in Malaysia, namely National University Hospital (NUH), National Cancer Centre Singapore (NCCS), Tan Tock Seng Hospital (TTSH), KK Women\'s and Children\'s Hospital (KKH), and University Malaya Medical Centre (UMMC). The hospitals started their hospital‐based breast cancer registries in different years, with the years of diagnosis of the patients between 1993 and 2013. This study was approved by National Healthcare Group Domain Specific Review Board, SingHealth Centralised Institutional Review Board, and UMMC Medical Ethics Committee.

Clinicopathologic information such as tumor grade, estrogen receptor (ER), progesterone receptor (PR) and HER2 status, clinical tumor size, clinical lymph node status and histological type were collected at all five hospitals using a standardized form. Basic patient demographics such as age at diagnosis and ethnicity were included. Tumor grade was evaluated according to the Elston--Ellis modification of Scarff--Bloom--Richardson grading system. If pretreatment biopsy tumor grade was not available, posttreatment grade was recorded, although it is noted that the latter may not accurately reflect original grade due to neoadjuvant chemotherapy effect. ER and PR status were determined via immunohistochemical staining either during core biopsies or using specimen from operation. Positive hormonal receptor status was deemed when 1% or more cells stained positive at NUH or 10% or more positively stained tumor cells at all other hospitals. HER2 status was based on fluorescence in situ hybridization (FISH) or immunohistochemistry (IHC) if FISH was not performed. HER2 positive was defined as FISH positive or IHC score of 3+, negative was defined as FISH negative or IHC scored of 0 or 1+, while equivocal was defined as IHC score of 2+ without confirmatory FISH test. For HER2 status, the data were not available before mid‐2000 for NUH and the completeness of this variable for UMMC is lower across the study period. All breast cancers were staged according to the 7th edition of TNM classification by American Joint Committee on Cancer (AJCC) [19](#cam4985-bib-0019){ref-type="ref"}. Treatment data consisted consist of type of type of neoadjuvant chemotherapy regimens (taxane containing vs. nontaxane containing) as well as type of surgery (mastectomy or breast‐conserving surgery). Use of preoperative anti‐HER2 therapy was only systematically recorded in registries at KKH and NCCS. Outcomes postneoadjuvant chemotherapy included size of invasive residual tumors resected, number of lymph nodes resected, and number of lymph nodes involved with tumor. All the databases from the five hospitals were subsequently merged.

Two definitions of pCR to neoadjuvant chemotherapy were used in this paper. The first definition of pCR (pCR (ypT0/is) in Table [1](#cam4985-tbl-0001){ref-type="table-wrap"}) requires no invasive residual tumors in the breast but allows for in situ disease, regardless of pathologic nodal status [20](#cam4985-bib-0020){ref-type="ref"}, [21](#cam4985-bib-0021){ref-type="ref"}. In the second definition, pCR (pCR (ypT0/is ypN0) in Table [1](#cam4985-tbl-0001){ref-type="table-wrap"}) is defined as no invasive residual disease in both breast and axillary lymph nodes but allows for in situ disease, as patients who are found to have invasive residual disease in the nodes with complete response in the breast have worse prognosis than those who had pCR in both breast and nodes [22](#cam4985-bib-0022){ref-type="ref"}, [23](#cam4985-bib-0023){ref-type="ref"}.

###### 

Demographics, clinicopathologic information, and treatments of breast cancer patients who underwent neoadjuvant chemotherapy at five public hospitals in Singapore and Malaysia (*N* = 915)

  No. of neoadjuvant cases                    KKH103    NUH181     NCCS302    TTSH137    UMMC192    Total915
  ------------------------------------------- --------- ---------- ---------- ---------- ---------- ----------
  Median follow‐up time (months)              36        57.5       33         34         32         38
  pCR (ypT0/is)                                                                                     
  Yes                                         1918.4%   147.7%     5618.5%    2216.1%    2513.0%    13614.9%
  No                                          7673.8%   15585.6%   23176.5%   10073.0%   5026.0%    61266.9%
  Unknown                                     87.8%     126.6%     155.0%     1510.9%    11760.9%   16718.3%
  pCR(ypT0/is ypN0)                                                                                 
  Yes                                         1615.5%   126.6%     5217.2%    1913.9%    2211.5%    12113.2%
  No                                          8279.6%   16189.0%   24179.8%   10677.4%   12464.6%   71478.0%
  Unknown                                     54.9%     84.4%      93.0%      128.8%     4624.0%    808.7%
  Age                                                                                               
  \<=34                                       1110.7%   105.5%     124.0%     85.8%      2513.0%    667.2%
  35--44                                      2221.4%   3821.0%    5417.9%    2518.2%    5528.6%    19421.2%
  45--54                                      3937.9%   7541.4%    12441.1%   4835.0%    7338.0%    35939.2%
  55--64                                      2019.4%   4625.4%    8528.1%    3827.7%    3116.1%    22024.0%
  65--74                                      87.8%     116.1%     278.9%     1611.7%    84.2%      707.7%
  \>=75                                       32.9%     00.0%      00.0%      21.5%      00.0%      50.5%
  Unknown                                     00.0%     10.6%      00.0%      00.0%      00.0%      10.1%
  Ethnicity                                                                                         
  Chinese                                     7068.0%   10658.6%   21069.5%   7957.7%    10655.2%   57162.4%
  Indian                                      87.8%     158.3%     196.3%     42.9%      199.9%     657.1%
  Malay                                       1413.6%   5329.3%    4615.2%    2518.2%    5930.7%    19721.5%
  Others                                      1110.7%   73.9%      278.9%     2921.2%    84.2%      829.0%
  ER status                                                                                         
  Positive                                    5957.3%   10859.7%   17056.3%   8259.9%    7639.6%    49554.1%
  Negative                                    4442.7%   6938.1%    12842.4%   5137.2%    9650.0%    38842.4%
  Unknown                                     00%       42.2%      41.3%      42.9%      2010.4%    323.5%
  PR status                                                                                         
  Positive                                    5149.5%   10960.2%   15651.7%   6245.3%    5126.6%    42946.9%
  Negative                                    5250.5%   6737.0%    14146.7%   6950.4%    8745.3%    41645.5%
  Unknown                                     00.0%     52.8%      51.7%      64.4%      5428.1%    707.7%
  HER2 status                                                                                       
  Positive                                    3332.0%   4524.9%    9932.8%    5036.5%    6232.3%    28931.6%
  Negative                                    6967.0%   9753.6%    19263.6%   7856.9%    6935.9%    50555.2%
  Equivocal                                   11.0%     10.6%      00.0%      00.0%      00.0%      20.2%
  Unknown                                     00.0%     3821.0%    113.6%     96.6%      6131.8%    11913.0%
  Grade                                                                                             
  1                                           1211.7%   63.3%      175.6%     1712.4%    52.6%      576.2%
  2                                           3534.0%   5731.5%    7926.2%    3626.3%    4925.5%    25628.0%
  3                                           4846.6%   10960.2%   11237.1%   5036.5%    8041.7%    39943.6%
  Unknown                                     87.8%     95.0%      9431.1%    3424.8%    5830.2%    20322.2%
  cT[a](#cam4985-note-0004){ref-type="fn"}                                                          
  T1                                          54.9%     00.0%      20.7%      53.6%      00.0%      121.3%
  T2                                          3332.0%   2614.4%    3411.3%    3827.7%    00.0%      13114.3%
  T3                                          2221.4%   5832.0%    9832.5%    3424.8%    00.0%      21223.2%
  T4                                          4240.8%   6938.1%    11839.1%   5741.6%    00.0%      28631.3%
  Unknown                                     11.0%     2815.5%    5016.6%    32.2%      192100%    27429.9%
  cN[b](#cam4985-note-0005){ref-type="fn"}                                                          
  N0                                          00.0%     2815.5%    4615.2%    2417.5%    00.0%      9810.7%
  N1                                          00.0%     4323.8%    13143.4%   5540.1%    00.0%      22925.0%
  N2                                          00.0%     2413.3%    4113.6%    2820.4%    00.0%      9310.2%
  N3                                          00.0%     137.2%     4113.6%    2619.0%    00.0%      808.7%
  Unknown                                     103100%   7340.3%    4314.2%    42.9%      192100%    41545.4%
  ypT[c](#cam4985-note-0006){ref-type="fn"}                                                         
  Tis                                         98.7%     52.8%      103.3%     96.6%      00.0%      333.6%
  T0                                          109.7%    95.0%      4615.2%    139.5%     2513.0%    10311.3%
  T1                                          2928.2%   5027.6%    5317.5%    3223.4%    147.3%     17819.5%
  T2                                          3635.0%   7139.2%    11437.7%   3827.7%    2010.4%    27930.5%
  T3                                          1110.7%   3418.8%    6421.2%    3021.9%    168.3%     15516.9%
  Unknown                                     87.8%     126.6%     155.0%     1510.9%    11760.9%   16718.3%
  ypN[d](#cam4985-note-0007){ref-type="fn"}                                                         
  N0                                          5553.4%   6636.5%    13444.4%   3928.5%    6935.9%    36339.7%
  N1                                          2423.3%   5128.2%    7223.8%    3021.9%    5830.2%    23525.7%
  N2                                          1514.6%   3016.6%    6019.9%    3324.1%    2915.1%    16718.3%
  N3                                          98.7%     2714.9%    299.6%     2417.5%    2010.4%    10911.9%
  Unknown                                     00.0%     73.9%      72.3%      118.0%     168.3%     414.5%
  Neoadjuvant chemotherapy regimen                                                                  
  Taxane containing                           9188.3%   12267.4%   22173.2%   11986.9%   3920.3%    59264.7%
  Nontaxane containing                        109.7%    5530.4%    8126.8%    96.6%      15379.7%   30833.7%
  Unknown                                     21.9%     42.2%      00.0%      96.6%      00.0%      151.6%
  Surgery type                                                                                      
  Breast‐conserving surgery                   2019.4%   3519.3%    134.3%     1410.2%    189.4%     10010.9%
  Mastectomy                                  8380.6%   14580.1%   28694.7%   12389.8%   17490.6%   81188.6%
  Unknown                                     00.0%     10.6%      31.0%      00.0%      00.0%      40.4%
  Radiotherapy                                                                                      
  Yes                                         8077.7%   14278.5%   26487.4%   7856.9%    17289.6%   73680.4%
  No                                          00.0%     2011.0%    309.9%     5640.9%    147.3%     12013.1%
  Unknown                                     2322.3%   1910.5%    82.6%      32.2%      63.1%      596.4%
  Adjuvant hormone therapy                                                                          
  Yes                                         5755.3%   12267.4%   19965.9%   5943.1%    3719.3%    47451.8%
  No                                          00.0%     4223.2%    9832.5%    7856.9%    9247.9%    31033.9%
  Unknown                                     4644.7%   179.4%     51.7%      00.0%      6332.8%    13114.3%

ER, estrogen receptor; TTSH, Tan Tock Seng Hospital; UMMC, University Malaya Medical Centre

preneoadjuvant chemotherapy clinical T stage.

preneoadjuvant clinical N stage.

postneoadjuvant chemotherapy pathologic T stage.

postneoadjuvant chemotherapy pathologic N stage.

John Wiley & Sons, Ltd

Vital status was obtained from the hospitals' medical records and ascertained by linkage to death registries in both countries. Patients were followed up from date of diagnosis until date of death or date of last follow‐up, whichever came first. Date of last follow‐up was 30th June 2014 for KKH, 31st July 2013 for NUH, 16th Jan 2014 for NCCS, 1st January 2014 for TTSH, and 1st March 2013 for UMMC. Based on the above definitions of follow‐up, all the patients in our study have follow‐up information.

Statistical analysis {#cam4985-sec-0003}
--------------------

Association between clinicopathologic variables and pCR was assessed using the Chi‐square test for univariate analysis and logistic regression for multivariate analysis. Patients were excluded from analysis if pCR (ypT0/is) (*N* = 167) or pCR (ypT0/is ypN0) (*N* = 80) status was not available. Overall survivals of patients with and without pCR were compared using Kaplan--Meier and log‐rank analyses, and further stratified by ER status and tumor grade. Hazard ratio (HR) and corresponding 95% confidence interval (CI) was estimated using Cox proportional hazards model. Only patients with vital status were included in survival analysis (*N* = 829). Two‐tailed *P* \< 0.05 was considered as statistically significant. IBM SPSS for Windows version 23.0 (SPSS Inc., Chicago, IL) was used to perform all statistical analysis for this study.

Results {#cam4985-sec-0004}
=======

In total, 4.4% of nonmetastatic patients registered in the hospital‐based registries received neoadjuvant chemotherapy, ranging from 3.1% to 6.6% across different hospitals, and from 1.3% to 10.8% across different stages. Summary of clinical and treatment characteristics of patients who received neoadjuvant chemotherapy from each participating hospital is presented in Table [1](#cam4985-tbl-0001){ref-type="table-wrap"}. In this study of Southeast Asian women, the median age of the patients was 50. Overall, Chinese made up the majority of the patients (571, 62.4%), followed by Malays (197, 21.5%) (Table [1](#cam4985-tbl-0001){ref-type="table-wrap"}). Histologically, 495 (54.1%) patients had tumors which were ER positive, 429 (46.9%) were PR positive, and 289 (31.6%) were HER2 positive (Table [1](#cam4985-tbl-0001){ref-type="table-wrap"}). Only a total of 100 (10.9%) patients eventually underwent breast‐conserving surgeries over the entire study period (Table [1](#cam4985-tbl-0001){ref-type="table-wrap"}).

Overall, 136 patients (18.1% after excluding patients with unknown pCR) and 121 patients (14.4%) achieved pCR (ypT0/is) and pCR (ypT0/is ypN0), respectively, following neoadjuvant chemotherapy. In univariate analysis, preneoadjuvant chemotherapy clinical T stage, grade of tumor, ER status, and HER2 status were significantly associated with pCR (ypT0/is) status (Table [2](#cam4985-tbl-0002){ref-type="table-wrap"}). Period of diagnosis, grade of tumor, ER status, HER2 status, and type of neoadjuvant chemotherapy were significantly associated with pCR (ypT0/is ypN0) (Table [2](#cam4985-tbl-0002){ref-type="table-wrap"}). After adjustment in multivariate analysis, ER and HER2 status were significant predictors for both pCR (ypT0/is) and pCR (ypT0/is ypN0). Patients with grade 3 tumor were significantly more likely to achieve pCR (ypT0/is ypN0) than grade 1 and 2 tumors. Further stratification has shown that pCR rate was highest in patients with HER2‐positive, ER‐negative, and grade 3 tumors (Table [3](#cam4985-tbl-0003){ref-type="table-wrap"}). For grade 2 and grade 3 tumors of same HER2 status, ER‐negative tumors had higher rate of pCR than ER‐positive tumors. pCR rate increased with higher tumor grade for tumors with similar HER2 and ER status. In subgroup analysis by ER, PR, and HER2 status, patients with ER‐negative, PR‐negative, and HER2‐positive tumors were most likely to obtain pCR than other subtypes (Table [4](#cam4985-tbl-0004){ref-type="table-wrap"}). A higher pCR rate was noted in patients who received taxane‐containing neoadjuvant regimen after correcting for other factors (Table [2](#cam4985-tbl-0002){ref-type="table-wrap"}). A sensitivity analysis was performed by removing cases with unknown clinicopathologic data. The results remained similar except for the lack of statistical significance for taxane‐containing regimen and increase in odds ratio for HER2‐positive tumor.

###### 

pCR rates of breast cancer patients who underwent neoadjuvant chemotherapy stratified by patient demographics, clinicopathologic, and treatment information

  *** ***                                    pCR (ypT0/is)(*N* = 748)   pCR (ypT0/is ypN0)(*N* = 835)                                                                                          
  ------------------------------------------ -------------------------- ------------------------------- ------------------------- ---------- ---------- ------------------------ ------------- ---
  Total                                      13618.2%                   61281.8%                                                             12114.5%   71485.5%                                
  Ethnicity                                                                                             0.983                                                                    0.651         
  Chinese                                    8918.5%                    39181.5%                        Ref                       7915.0%    44785.0%   Ref                                    
  Malay                                      2517.1%                    12182.9%                        1.06 (0.58, 1.93)         2212.7%    15187.3%   1.00 (0.55, 1.82)                      
  Indian                                     917.6%                     4282.4%                         1.72 (0.71,4.14)          711.3%     5588.7%    1.09 (0.42, 2.81)                      
  Others                                     1318.3%                    5881.7%                         0.96 (0.43, 2.14)         1317.6%    6182.4%    1.10 (0.50, 2.45)                      
  Period of diagnosis                                                                                   **0.001**                                                                **\<0.001**    
  1993--2004                                 1815.7%                    9784.3%                         Ref                       138.7%     13691.3%   Ref                                    
  2005--2008                                 3011.5%                    23288.5%                        1.19 (0.51, 2.74)         258.3%     27591.7%   1.36 (0.56, 3.27)                      
  2009--2013                                 8423.8%                    26976.2%                        1.96 (0.86, 4.43)         7921.5%    28978.5%   **3.43 (1.44, 8.16)**                  
  Unknown                                    422.2%                     1477.8%                         1.68 (0.38, 7.37)         422.2%     1477.8%    3.22 (0.71,14.67)                      
  Age                                                                                                   0.557                                                                    0.633          
  \<=34                                      1022.2%                    3577.8%                         Ref                       1017.2%    4882.8%    Ref                                    
  35--44                                     3120.5%                    12079.5%                        0.79 (0.30, 2.08)         2917.0%    14283.0%   1.06 (0.42, 2.70)                      
  45--54                                     5919.6%                    24280.4%                        0.91 (0.37, 2.27)         5215.3%    28784.7%   1.08 (0.44, 2.62)                      
  55--64                                     2815.1%                    15784.9%                        0.58 (0.22, 1.55)         2311.7%    17488.3%   0.70 (0.26, 1.82)                      
  65--74                                     813.3%                     5286.7%                         0.44 (0.13, 1.45)         710.9%     5789.1%    0.56 (0.17, 1.84)                      
  \>=75                                      00.0%                      5100.0%                         00.0%                     5100.0%                                                      
  Unknown                                    00.0%                      1100.0%                         0                         00.0%      1100.0%    0                                      
  cT[a](#cam4985-note-0008){ref-type="fn"}                                                              **0.011**                                                                0.316          
  T1                                         216.7%                     1083.3%                         Ref                       216.7%     1083.3%    Ref                                    
  T2                                         2419.5%                    9980.5%                         2117.1%                   10282.9%                                                     
  T3                                         3718.5%                    16381.5%                        0.66 (0.33, 1.31)         3315.9%    17484.1%   0.71 (0.35, 1.44)                      
  T4                                         3312.5%                    23087.5%                        **0.42 (0.21, 0.85)**     2910.7%    24289.3%   **0.45 (0.22, 0.93)**                  
  Tx                                         4026.7%                    11073.3%                        1.23 (0.60, 2.51)         3616.2%    18683.8%   1.00 (0.48, 2.08)                      
  Grade                                                                                                 **\<0.001**                                                              **\<0.001**   
  1                                          11.9%                      5198.1%                         Ref                       00.0%      56100.0%   Ref                                    
  2                                          146.5%                     20293.5%                        124.9%                    23495.1%                                                     
  3                                          4613.7%                    28986.3%                        1.86 (0.96, 3.61)         4211.5%    32288.5%   **2.14 (1.04, 4.38)**                  
  Unknown                                    7551.7%                    7048.3%                         **14.34 (7.19, 28.62)**   6739.6%    10260.4%   **10.95(5.30, 22.59)**                 
  ER status                                                                                             **\<0.001**                                                              **\<0.001**   
  Positive                                   419.7%                     38190.3%                        **0.41 (0.25,0.67)**      326.9%     43393.1%   **0.34 (0.20, 0.56)**                  
  Negative                                   8627.9%                    22272.1%                        Ref                       8023.2%    26576.8%   Ref                                    
  Unknown                                    950.0%                     950.0%                          0.65 (0.17, 2.51)         936.0%     1664.0%    0.88 (0.26, 3.02)                      
  HER2 status                                                                                           **\<0.001**                                                              **\<0.001**    
  Positive                                   6427.4%                    17072.6%                        **2.93 (1.77,4.84)**      6023.3%    19876.7%   **2.98 (1.79, 4.98)**                  
  Negative                                   4911.3%                    38388.7%                        Ref                       418.7%     42991.3%   Ref                                    
  Equivocal                                  00.0%                      2100.0%                         **3.44 (1.46,8.14)**      00.0%      2100.0%    **3.13 (1.30, 7.54)**                  
  Unknown                                    2328.8%                    5771.3%                         2019.0%                   8581.0%                                                      
  Neoadjuvant chemotherapy regimen                                                                      0.150                                                                    **0.008**      
  Taxane containing                          10519.9%                   42380.1%                        **2.12 (1.16,3.87)**      9517.2%    45882.8%   **2.58 (1.37, 4.87)**                  
  Nontaxane containing                       3014.4%                    17885.6%                        Ref                       259.3%     24490.7%   Ref                                    
  Unknown                                    18.3%                      1191.7%                         0.68 (0.07, 6.99)         17.7%      1292.3%    0.97 (0.10, 9.91)                      

preneoadjuvant chemotherapy clinical T stage.

Statistically significant values are formatted in bold.

John Wiley & Sons, Ltd

###### 

pCR rates of breast cancer patients who underwent neoadjuvant chemotherapy stratified by HER2, ER status, and grade

  HER2+                                                          
  --------- --------------- -------------------- --------------- --------------------
  Grade     pCR (ypT0/is)   pCR (ypT0/is ypN0)   pCR (ypT0/is)   pCR (ypT0/is ypN0)
  1         00.0%           00.0%                00.0%           00.0%
  2         38.6%           25.1%                417.4%          416.0%
  3         815.7%          610.7%               1725.0%         1621.0%
  Unknown   853.3%          850.0%               2468.6%         2461.5%

  HER2−                                                          
  --------- --------------- -------------------- --------------- --------------------
  Grade     pCR (ypT0/is)   pCR (ypT0/is ypN0)   pCR (ypT0/is)   pCR (ypT0/is ypN0)
  1         12.4%           00.0%                0--             00.0%
  2         21.7%           21.6%                15.9%           15.0%
  3         56.1%           44.7%                109.9%          109.3%
  Unknown   1127.5%         714.6%               1955.9%         1743.6%

ER, estrogen receptor. --, pCR rate can\'t be calculate with a zero denominator.

John Wiley & Sons, Ltd

###### 

pCR rates of breast cancer patients who underwent neoadjuvant chemotherapy stratified by ER, PR, and HER2 status

  *** ***             pCR (ypT0/is)(*N* = 510)   pCR (ypT0/is ypN0)(*N* = 560)                                                                                    
  ------------------- -------------------------- ------------------------------- ------------------------ --------- ---------- ------------------------ --------- -----
  ER+ PR+ and HER2−   125.4%                     21094.6%                        \<0.001                  Ref       93.8%      23096.2%                 \<0.001   Ref
  ER+ PR+ and HER2+   811.8%                     6088.2%                         2.39 (0.82, 7.00)        79.5%     6790.5%    2.74 (0.87,8.69)                   
  ER− PR− and HER2+   3030.3%                    6969.7%                         **6.35 (2.72, 14.81)**   2925.7%   8474.3%    **7.56 (3.07, 18.65)**             
  ER− PR− and HER2−   2520.7%                    9679.3%                         **3.00 (1.28,7.06)**     2317.2%   11182.8%   **3.84 (1.52,9.70)**               

ER**,** estrogen receptor.

Statistically significant values are formatted in bold.

adjusted for ethnicity, age, period of diagnosis, preneoadjuvant chemotherapy clinical T stage, grade, and neoadjuvant chemotherapy regimen.

John Wiley & Sons, Ltd

The median survival of patients receiving neoadjuvant chemotherapy was 11.4 years and overall 5‐year survival was 71.5%. pCR (ypT0/is) (HR = 0.54, 95% CI: 0.31--0.96) and pCR (ypT0/is ypN0) (HR = 0.29, 95% CI: 0.13--0.61) were significant predictors for overall survival (Fig. [1](#cam4985-fig-0001){ref-type="fig"}A and [1](#cam4985-fig-0001){ref-type="fig"}B). Among patients with ER‐negative tumors, those who achieved pCR (ypT0/is) (HR = 0.30, 95% CI: 0.14--0.66) and pCR (ypT0/is ypN0) (HR = 0.15, 95% CI: 0.06, 0.41) had a significantly better survival (Fig. [2](#cam4985-fig-0002){ref-type="fig"}A and B). pCR (ypT0/is) status was not associated with overall survival among patients with ER‐positive tumors (Fig. [2](#cam4985-fig-0002){ref-type="fig"}A), grade 1 and 2 tumors, and grade 3 tumors (Fig. [3](#cam4985-fig-0003){ref-type="fig"}A). pCR (ypT0/is ypN0) was a significant prognosticator for grade 3 tumors (Fig. [3](#cam4985-fig-0003){ref-type="fig"}B) but not for ER‐positive (Fig. [2](#cam4985-fig-0002){ref-type="fig"}B) and grade 1 and 2 tumors (Fig. [3](#cam4985-fig-0003){ref-type="fig"}B).

![Kaplan--Meier survival curves by (A) pCR (ypT0/is) and (B) pCR (ypT0/is ypN0).](CAM4-6-173-g001){#cam4985-fig-0001}

![Kaplan--Meier survival curves by (A) estrogen receptor (ER) status and pCR (ypT0/Tis) and (B) ER status and pCR (ypT0/Tis ypN0).](CAM4-6-173-g002){#cam4985-fig-0002}

![Kaplan--Meier survival curves by (A) tumor grade and pCR (ypT0/Tis) and (B) tumor grade and pCR (ypT0/Tis ypN0).](CAM4-6-173-g003){#cam4985-fig-0003}

Discussion {#cam4985-sec-0005}
==========

In our study population, 4.4% of all nonmetastatic breast cancer patients received neoadjuvant chemotherapy. Although the number of patients diagnosed with breast cancer increased over time, there was no increase in the proportion of nonmetastatic breast cancer patients who were treated with neoadjuvant chemotherapy over the years. pCR rates among breast cancer patients who underwent neoadjuvant chemotherapy were 18.1% (ypT0/is) and 14.4% (ypT0/is ypN0), respectively. Positive HER2 status, negative ER status, and use of taxane‐containing regimen were significant positive predictors for pCR after adjustment for other factors. pCR is associated with better survival among all neoadjuvant patients, and in particular, in patients with ER‐negative tumor.

The incidence of breast cancer is increasing in Asia. As most women present with stage II and above breast cancer [24](#cam4985-bib-0024){ref-type="ref"}, neoadjuvant chemotherapy plays an important role in the treatment of breast cancer. Thus far, most pCR rates reported in Asian studies, ranging from 5.9% to 15% [25](#cam4985-bib-0025){ref-type="ref"}, [26](#cam4985-bib-0026){ref-type="ref"}, [27](#cam4985-bib-0027){ref-type="ref"}, were observed from clinical trials of neoadjuvant chemotherapy or single institutional study with very small sample size, which might be different from actual clinical practice. The pCR rate reported in the present study is comparable to results from other observational studies, as well as the National Surgical Adjuvant Breast and Bowel Project (NSABP) B‐18 trial, in which patients received pre‐operative doxorubicin and cyclophosphamide (AC). However, our pCR rate is much lower than those treated with AC followed by docetaxel in the more recent NSABP B‐27 trial [7](#cam4985-bib-0007){ref-type="ref"}, [8](#cam4985-bib-0008){ref-type="ref"}, [9](#cam4985-bib-0009){ref-type="ref"}. The meta‐analysis by Mazouni et al. revealed a similar trend as the NSABP B‐27 trial that patients with both ER‐positive and ER‐negative tumors had higher rate of pCR when taxane are added into the regime [17](#cam4985-bib-0017){ref-type="ref"}. As 64.7% of patients received taxane as part of their neoadjuvant regimen in this study, our results may also reflect the difference in clinical profile such as larger inoperable tumor and treatment decision between clinical trials and actual practice.

The distribution of the various races of patients who underwent neoadjuvant therapy in Singapore fits the general distribution of ethnicity of the breast cancer patients in Singapore [28](#cam4985-bib-0028){ref-type="ref"}. Chinese patients, as the largest ethnic group in Singapore, were more likely to have breast cancer based on age‐standardized incidence rate and this corresponded to a higher proportion of Chinese who underwent neoadjuvant therapy. However, a closer examination will reveal that the distribution of Malay patients who underwent neoadjuvant therapy for breast cancer is also higher than the distribution of Malay breast cancer patients found in population‐based cancer registry in Singapore (10.9% during 2006--2010) and an earlier published hospital‐based study conducted in Singapore and Malaysia (16% during 1990--2007) [14](#cam4985-bib-0014){ref-type="ref"}. Of the patients who had their treatment at UMMC, there was a higher proportion of Chinese as the residents of its catchment were mainly of middle income and Chinese descent, although Malays are the majority ethnic group in Malaysia [14](#cam4985-bib-0014){ref-type="ref"}, [29](#cam4985-bib-0029){ref-type="ref"}. Previous studies have shown that Malay patients were more likely to present with larger tumor and later stage, as compared to their Chinese counterparts [30](#cam4985-bib-0030){ref-type="ref"}. This may result in more Malay patients selected for neoadjuvant therapy.

Patients with worse prognostic tumor profile such as higher grade, ER negativity, and HER2 positivity were found to have better response to neoadjuvant chemotherapy. Specifically, patients with tumor profile of ER negativity, PR negativity, and HER2 positivity had the highest rate of pCR among the four major breast cancer subtypes. This result corresponds to the published findings [21](#cam4985-bib-0021){ref-type="ref"}, [31](#cam4985-bib-0031){ref-type="ref"} and is consistent with many other studies and a recent meta‐analysis suggested pCR paradox [32](#cam4985-bib-0032){ref-type="ref"}, [33](#cam4985-bib-0033){ref-type="ref"}, [34](#cam4985-bib-0034){ref-type="ref"}, [35](#cam4985-bib-0035){ref-type="ref"}, whereby patients with more aggressive tumors responded better to neoadjuvant chemotherapy. However, given that 54.1% of patients had ER‐positive tumors and 31.6% had HER2‐positive tumors, our pCR rate of 18.1% (ypT0/is) and 14.4% (ypT0/is ypN0) seems to be low. This is likely a result of Asian women having smaller breast size but presenting with higher stage tumors [36](#cam4985-bib-0036){ref-type="ref"}. Therefore, neoadjuvant chemotherapy aids in shrinking the size of the tumor instead of directly leading to pCR status.

In our present analysis, pCR is significantly associated with better survival. Subgroup analysis has demonstrated the limitation of pCR for prognostication as pCR is only informative for ER‐negative tumor. This is also observed in other pooled analyses of clinical trials [21](#cam4985-bib-0021){ref-type="ref"}, [31](#cam4985-bib-0031){ref-type="ref"}.

A meta‐analysis of 14 randomized trials demonstrated that neoadjuvant chemotherapy could reduce mastectomy by 16.6% comparing to adjuvant chemotherapy [37](#cam4985-bib-0037){ref-type="ref"}. In this study, even though the rate of pCR is comparable to other countries, the proportion of patients who underwent breast‐conserving surgery after neoadjuvant chemotherapy is noted to be markedly lower (10.9%) than the percentage of 13% to 83% reported in other studies [38](#cam4985-bib-0038){ref-type="ref"}. This could be due to smaller breast size among Asian women, larger proportion of advanced‐stage and socio‐cultural factors which may affect patients' choice between mastectomy and breast‐conserving surgery [39](#cam4985-bib-0039){ref-type="ref"}. More studies should be done to find out the reasons for the lower rate of breast‐conserving surgeries in the Asian population.

A strength of the study is its multi‐institutional design which makes our study one of the largest studies done in Asia to determine the demographics of breast cancer patients who underwent neoadjuvant chemotherapy, clinicopathologic predictors for response to treatment, and their long‐term survival in an actual clinical practice setting.

However, the study is not without its limitations. Due to the retrospective nature of the study, some variables were not completely collected for analysis in this study. As regular testing of HER2 was not done before the mid‐2000 in selected hospitals in this study, a proportion of data were missing, and hence, reduced the available sample size for the analysis of the pCR paradox. Grade is more likely to be missing for patients with pCR as no residual tumor was left for pathologic assessment on grade and grade was not commonly evaluated during biopsy in some participating hospitals. This selective loss of data may depend on the value itself as higher grade was more likely to achieve pCR and thus restrict our ability to estimate association between grade and pCR rate. Different cut‐off point for ER status was used for patients from NUH but sensitivity analysis by excluding NUH cases from relevant analyses did not change the interpretation of results.

In conclusion, patients with worse prognostic profile based on ER and HER2 status are more likely to respond to neoadjuvant chemotherapy in the real‐world setting in Asia and pCR is associated with better overall survival especially for patients with ER‐negative tumor.
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